Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

BACKGROUND: Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colorectal cancer (CRC), non-small-cell lung cancer (...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Garcia-Carbonero, Rocio, Salazar, Ramon, Duran, Ignacio, Osman-Garcia, Ignacio, Paz-Ares, Luis, Bozada, Juan M., Boni, Valentina, Blanc, Christine, Seymour, Len, Beadle, John, Alvis, Simon, Champion, Brian, Calvo, Emiliano, Fisher, Kerry
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604344/
https://ncbi.nlm.nih.gov/pubmed/28923104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0277-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы